TWI617549B - 作為鈣感測受體調節劑之取代二氫苯並哌喃化合物 - Google Patents

作為鈣感測受體調節劑之取代二氫苯並哌喃化合物 Download PDF

Info

Publication number
TWI617549B
TWI617549B TW102106358A TW102106358A TWI617549B TW I617549 B TWI617549 B TW I617549B TW 102106358 A TW102106358 A TW 102106358A TW 102106358 A TW102106358 A TW 102106358A TW I617549 B TWI617549 B TW I617549B
Authority
TW
Taiwan
Prior art keywords
methyl
ethyl
amino
dihydrobenzopiperan
naphthalene
Prior art date
Application number
TW102106358A
Other languages
English (en)
Chinese (zh)
Other versions
TW201336831A (zh
Inventor
曼諾庫馬爾 拉姆普拉 蘇克拉
Manojkumar Ramprasad Shukla
安庫許 岡格朗 沙德
Ankush Gangaram Sarde
瑞傑許庫馬爾 馬詹拉 羅利亞
Rajeshkumar Maganlal Loriya
凡保 德利普 佩屈普特
Vipul Dilip Pachpute
那維斯 巴吉勞 沃爾克
Navnath Bajirao Walke
塔爾哈 胡賽因 卡恩
Talha Hussain Khan
桑吉夫 安納特 庫爾卡尼
Sanjeev Anant Kulkarni
凡卡塔 帕勒
Venkata P. Palle
瑞傑德 庫馬爾 坎柏
Rajender Kumar Kamboj
Original Assignee
印度商魯賓有限公司
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 印度商魯賓有限公司, Lupin Limited filed Critical 印度商魯賓有限公司
Publication of TW201336831A publication Critical patent/TW201336831A/zh
Application granted granted Critical
Publication of TWI617549B publication Critical patent/TWI617549B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
TW102106358A 2012-02-24 2013-02-23 作為鈣感測受體調節劑之取代二氫苯並哌喃化合物 TWI617549B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN178/KOL/2012 2012-02-24
IN178KO2012 2012-02-24
IN1030KO2012 2012-09-07
IN1030/KOL/2012 2012-09-07

Publications (2)

Publication Number Publication Date
TW201336831A TW201336831A (zh) 2013-09-16
TWI617549B true TWI617549B (zh) 2018-03-11

Family

ID=54261188

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102106358A TWI617549B (zh) 2012-02-24 2013-02-23 作為鈣感測受體調節劑之取代二氫苯並哌喃化合物

Country Status (44)

Country Link
US (3) US9163001B2 (enExample)
EP (1) EP2817299B1 (enExample)
JP (1) JP6114316B2 (enExample)
KR (1) KR102041154B1 (enExample)
CN (1) CN104350047B (enExample)
AP (1) AP2014007919A0 (enExample)
AR (1) AR090135A1 (enExample)
AU (1) AU2013223715B2 (enExample)
BR (1) BR112014021133B1 (enExample)
CA (1) CA2864332C (enExample)
CL (1) CL2014002218A1 (enExample)
CO (1) CO7160018A2 (enExample)
CR (1) CR20140424A (enExample)
CU (1) CU24325B1 (enExample)
CY (1) CY1122017T1 (enExample)
DK (1) DK2817299T3 (enExample)
DO (1) DOP2014000193A (enExample)
EA (1) EA026940B9 (enExample)
ES (1) ES2743492T3 (enExample)
GE (2) GEAP201813579A (enExample)
GT (1) GT201400179A (enExample)
HR (1) HRP20191606T1 (enExample)
HU (1) HUE046172T2 (enExample)
IL (1) IL234252A (enExample)
IN (1) IN2014MN01672A (enExample)
LT (1) LT2817299T (enExample)
MA (1) MA35937B1 (enExample)
MX (1) MX355670B (enExample)
MY (1) MY171374A (enExample)
NI (1) NI201400094A (enExample)
NZ (1) NZ628627A (enExample)
PE (1) PE20142281A1 (enExample)
PH (1) PH12014501891B1 (enExample)
PL (1) PL2817299T3 (enExample)
PT (1) PT2817299T (enExample)
RS (1) RS59172B1 (enExample)
SG (1) SG11201405117SA (enExample)
SI (1) SI2817299T1 (enExample)
SM (1) SMT201900506T1 (enExample)
TN (1) TN2014000352A1 (enExample)
TW (1) TWI617549B (enExample)
UA (1) UA112679C2 (enExample)
WO (1) WO2013124828A1 (enExample)
ZA (1) ZA201405990B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102041154B1 (ko) * 2012-02-24 2019-11-07 루핀 리미티드 칼슘 감지 수용체 조절자로서의 치환 크로만 화합물
HK1211916A1 (en) * 2012-08-27 2016-06-03 Lupin Atlantis Holdings Sa Arylalkylamine compounds as calcium sensing receptor modulators
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
US9493396B2 (en) 2013-08-28 2016-11-15 Lupin Atlantis Holdings Sa Substituted naphthalene compounds as calcium sensing receptor modulators
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
PH12022551057A1 (en) * 2019-11-19 2023-09-18 Lupin Ltd Process for preparing chroman compounds
AU2020415502A1 (en) 2019-12-27 2022-07-14 Lupin Limited Pharmaceutical composition of CaSR modulators and methods and uses thereof
SI4090654T1 (sl) * 2020-01-17 2025-11-28 Lupin Ltd. Metode, postopki in intermediati za pripravo kromanskih spojin
WO2025255092A1 (en) * 2024-06-03 2025-12-11 Artax Biopharma Inc. Combination of a chromene derivative tcr inhibitor and a tyk2 inhibitor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3063585D1 (en) * 1979-05-19 1983-07-07 Beecham Group Plc Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them
US5387587A (en) * 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
CA2527203C (en) 2003-05-28 2010-08-17 Japan Tobacco Inc. Casr antagonist
EP1882684B1 (en) 2005-05-19 2014-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
TW200815388A (en) 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
CA2663436A1 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
MX2009003981A (es) * 2006-10-26 2009-04-27 Amgen Inc Agentes moduladores del receptor de calcio.
WO2008059854A1 (en) 2006-11-16 2008-05-22 Astellas Pharma Inc. Piperidine derivatives or salts thereof
US8334317B2 (en) * 2007-10-15 2012-12-18 Amgen Inc. Calcium receptor modulating agents
CA2706076A1 (en) 2007-11-23 2009-05-28 Leo Pharma A/S Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2010038895A1 (ja) 2008-10-03 2010-04-08 味の素株式会社 CaSRアゴニスト
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体
WO2012069421A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
CN103270018A (zh) 2010-11-26 2013-08-28 利奥制药有限公司 钙敏感受体激活化合物
AU2012226375B2 (en) 2011-03-10 2017-04-13 Lupin Atlantis Holdings Sa Substituted morpholines as modulators for the calcium sensing receptor
SG193331A1 (en) 2011-03-18 2013-10-30 Lupin Ltd Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
KR102041154B1 (ko) * 2012-02-24 2019-11-07 루핀 리미티드 칼슘 감지 수용체 조절자로서의 치환 크로만 화합물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lionel Kiefer ET AL, "Design and synthesis of cyclic sulfonamides and sulfamates as new calcium sensing receptor agonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, Vol 20(24), 2010, pages 7483-7487. *
Lionel Kiefer ET AL, "Novel calcium sensing receptor ligands: a patent survey", Expert Opin. Ther. Patents, Vol 21(5), 2011,pages 681-698. *

Also Published As

Publication number Publication date
SI2817299T1 (sl) 2019-10-30
GT201400179A (es) 2016-03-01
US9598391B2 (en) 2017-03-21
PT2817299T (pt) 2019-09-23
JP6114316B2 (ja) 2017-04-12
TN2014000352A1 (en) 2015-12-21
PH12014501891A1 (en) 2015-02-09
RS59172B1 (sr) 2019-10-31
DOP2014000193A (es) 2017-01-15
EA201491582A1 (ru) 2014-12-30
IN2014MN01672A (enExample) 2015-05-29
CU20140103A7 (es) 2015-01-29
EP2817299A1 (en) 2014-12-31
GEP20186911B (en) 2018-10-25
ES2743492T3 (es) 2020-02-19
US20150038546A1 (en) 2015-02-05
TW201336831A (zh) 2013-09-16
CU24325B1 (es) 2018-03-13
CR20140424A (es) 2015-01-13
MA35937B1 (fr) 2014-12-01
CA2864332A1 (en) 2013-08-29
MX355670B (es) 2018-04-25
EA026940B1 (ru) 2017-06-30
JP2015508097A (ja) 2015-03-16
ZA201405990B (en) 2015-11-25
PL2817299T3 (pl) 2019-12-31
EA026940B9 (ru) 2017-11-30
CY1122017T1 (el) 2020-10-14
BR112014021133B1 (pt) 2022-06-28
HK1205117A1 (en) 2015-12-11
AR090135A1 (es) 2014-10-22
AP2014007919A0 (en) 2014-09-30
CL2014002218A1 (es) 2015-03-06
SMT201900506T1 (it) 2019-11-13
US20150368222A1 (en) 2015-12-24
CO7160018A2 (es) 2015-01-15
LT2817299T (lt) 2019-09-25
PH12014501891B1 (en) 2021-05-05
MY171374A (en) 2019-10-10
DK2817299T3 (da) 2019-09-16
HRP20191606T1 (hr) 2019-12-13
PE20142281A1 (es) 2015-01-16
AU2013223715B2 (en) 2017-09-14
KR20140135731A (ko) 2014-11-26
CA2864332C (en) 2020-08-25
MX2014010139A (es) 2015-09-04
US20170209410A1 (en) 2017-07-27
HUE046172T2 (hu) 2020-02-28
US9987249B2 (en) 2018-06-05
SG11201405117SA (en) 2014-09-26
CN104350047A (zh) 2015-02-11
US9163001B2 (en) 2015-10-20
WO2013124828A1 (en) 2013-08-29
IL234252A (en) 2017-02-28
EP2817299B1 (en) 2019-06-12
AU2013223715A1 (en) 2014-08-28
BR112014021133A2 (en) 2018-09-11
GEAP201813579A (en) 2018-06-25
CN104350047B (zh) 2017-05-24
UA112679C2 (uk) 2016-10-10
NZ628627A (en) 2017-02-24
NI201400094A (es) 2015-03-27
KR102041154B1 (ko) 2019-11-07

Similar Documents

Publication Publication Date Title
KR102041154B1 (ko) 칼슘 감지 수용체 조절자로서의 치환 크로만 화합물
CN111801324A (zh) 甲状腺激素受体激动剂及其用途
EP2686306A1 (en) Benzo [b][1, 4]oxazin derivatives as calcium sensing receptor modulators
TW201706275A (zh) 具有hiv複製抑制作用之含氮3環性衍生物
WO2018041248A1 (zh) Bcl-2选择性抑制剂及其制备和用途
WO2015162538A1 (en) Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
WO2013136288A1 (en) Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
CN104583177B (zh) 作为钙敏感受体调节剂的芳基烷基胺化合物
TW200922943A (en) Compounds
ES2348838T3 (es) Compuestos de cicloalquilideno como moduladores slectivos del receptor de estrã“genos.
EP3039014A1 (en) Substituted naphthalene compounds as calcium sensing receptor modulators
WO2017037616A1 (en) Arylalkylamine compounds as calcium sensing receptor modulators
WO2025108106A1 (zh) 一种含喹啉酮骨架的化合物及其应用
WO2026052060A1 (zh) 一类苯甲酰基甘氨酸衍生物及其制备方法和应用
CN107614484A (zh) 用于治疗肾脏和/或肝脏疾病的组合物
HK1205117B (en) Substituted chroman compounds as calcium sensing receptor modulators
JP2008543741A (ja) 新規な化合物

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees